Subscribe   RSS Contact Us

New Memorandum Spells Out FDA’s First Amendment Position on Off-label Use Promotion

Jan. 20, 2017 – The FDA effectively delayed any prompt action on new guidance covering the promotion of unapproved or ... read more

Marketing Tax Provision Escapes Senate Vote

Jan. 13, 2017 – An amendment introduced by Sen. Al Franken (D-Minn.) to eliminate the tax deduction for drug marketing ... read more

FDA Will Study Consumer and HCP Ability to Identify Deceptive Drug Promotion

Jan. 4, 2017 – The FDA will examine whether consumers and health care professionals (HCPs) can identify deceptive claims in ... read more

OPDP Cites Two Companies for YouTube Videos Featuring INDs

Jan. 3, 2017 – In its last blast of 2016, the FDA’s Office of Prescription Drug Promotion (OPDP) sent Untitled ... read more

OPDP Sends Two Letters Citing Major Statement Treatment in TV Ad Claims

Dec. 15, 2016 – Television ads allegedly making false and misleading claims about the risks associated with their products were ... read more

Previous Next

Coalition’s Role

The Coalition’s role is first, to defend the rights of medical professionals and consumers to receive appropriate healthcare information, and second, to act to prevent or reverse actions interfering with the free flow of healthcare information.

Whenever open communication regarding a pharmaceutical or medical product is obstructed, the Coalition proactively explores ways to break down barriers. Issues are raised and discussed in depth at regular executive monthly committee meetings, typically held in New York City. Subcommittees are often formed to research specific topics and propose solutions to the larger group.

Once the Coalition thoroughly investigates an issue, it formulates a position that reflects the concerns and desires of its member organizations. Often, it seeks input from other important authoritative bodies.